Drug manufacturers Sun Pharmaceutical Industries, Glenmark Pharmaceuticals, and Alembic Pharmaceuticals are issuing recalls for multiple products in the United States following manufacturing problems, as reported by the US Food and Drug Administration (USFDA).
Glenmark Pharmaceuticals, based in Mumbai, is recalling Carvedilol tablets through its US subsidiary, Glenmark Pharmaceuticals Inc, USA. These tablets are commonly prescribed for heart failure, hypertension, and heart attack treatment in various strengths. The recall affects 55,560 units due to the presence of N-Nitroso Carvedilol impurity exceeding acceptable levels, along with 17,496 bottles where the NNCI impurity surpassed FDA-recommended limits.
In addition, Glenmark is recalling 22,656 bottles of Theophylline extended-release tablets due to failed dissolution specifications. These actions were classified as Class II recalls and were initiated in August this year to address potential health consequences.
Alembic Pharmaceuticals is also part of the recall, pulling back 9,492 bottles of Doxepin Hydrochloride capsules used for treating insomnia. The reason cited for this Class II recall is the presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit, with the recall initiated in July.
Sun Pharmaceutical Industries, based in New Jersey, is recalling 11,328 bottles of Spironolactone Tablets, a medication for high blood pressure, due to the presence of aluminum contaminants. This Class II recall began in August to prevent potential health risks to consumers.
According to the USFDA, a Class II recall is triggered when exposure to a defective product might cause temporary or reversible health issues, with minimal likelihood of serious adverse outcomes. These actions underline the commitment of these companies to product safety and regulatory compliance, ensuring consumer well-being.
Ruchika Sharma, a correspondent at Medical Dialogue, tracks pharmaceutical updates, policy developments, insurance trends, and business healthcare news. With a background in commerce and a postgraduate degree in finance, she brings a unique perspective to her reporting, connecting the dots between business and healthcare.
Dr. Kamal Kant Kohli, a seasoned chest specialist and Chief Editor at Medical Dialogues, leverages his 30 years of clinical experience to ensure accuracy and relevance in medical news coverage. His meticulous approach to editing ensures that all medical content meets the highest standards of authenticity and credibility.
These recalls serve as a reminder of the pharmaceutical industry’s continuous commitment to product quality and consumer safety. By swiftly addressing manufacturing discrepancies and potential health risks, companies like Sun Pharma, Glenmark, and Alembic uphold their responsibility to deliver safe and effective medications to patients in the US market.
Key Takeaways:
– Mumbai-based pharmaceutical companies Sun Pharma, Glenmark, and Alembic are recalling products in the US due to manufacturing issues identified by the USFDA.
– The recalls involve medications such as Carvedilol tablets, Theophylline extended-release tablets, Doxepin Hydrochloride capsules, and Spironolactone Tablets.
– These Class II recalls aim to prevent temporary or reversible health consequences from exposure to defective products, emphasizing the companies’ dedication to consumer safety and regulatory compliance.
– Through diligent reporting and editorial oversight, Medical Dialogues ensures that medical news is accurate, informative, and upholds the highest standards of credibility and authenticity.
Read more on medicaldialogues.in